Pediatric Asthma Exacerbation
Critical Alerts
- Silent chest is ominous: No wheezing may mean severe obstruction
- Hypoxia is a late sign: Respiratory fatigue and hypercapnia precede
- Magnesium for severe asthma: 40-75 mg/kg IV (max 2g)
- Continuous albuterol for severe cases: Not just PRN
- Early steroids reduce admissions: Give within 1 hour
- Don't delay intubation if indicated: But try to avoid
Key Diagnostics
| Test | Finding | Significance |
|---|---|---|
| SpO2 | <92% on room air | Severe exacerbation |
| Peak flow | <50% predicted | Severe exacerbation |
| Respiratory rate | Age-appropriate elevation | Severity marker |
| Work of breathing | Retractions, accessory muscles | Severity marker |
| Mental status | Agitation → lethargy | Impending failure |
Emergency Treatments (Pediatric Dosing)
| Intervention | Dose | Notes |
|---|---|---|
| Albuterol nebulizer | 2.5-5 mg q20min × 3, then hourly | Or continuous 0.5 mg/kg/hr |
| Ipratropium | 250-500 mcg q20min × 3 | Add to albuterol for severe |
| Prednisolone/Prednisone | 1-2 mg/kg PO (max 60 mg) | Within first hour |
| Dexamethasone | 0.6 mg/kg PO/IM (max 16 mg) | Single dose alternative |
| Magnesium sulfate | 40-75 mg/kg IV (max 2g) | For severe, over 20 min |
| Epinephrine IM | 0.01 mg/kg (1:1000), max 0.3-0.5 mg | Impending respiratory failure |
Overview
Acute asthma exacerbation in children is an episode of progressive worsening of asthma symptoms including cough, wheeze, chest tightness, and dyspnea, accompanied by decreased expiratory airflow. It ranges from mild exacerbations manageable at home to severe, life-threatening attacks requiring intensive care.
Classification by Severity
GINA/EPR-3 Severity Assessment:
| Severity | Symptoms | SpO2 | Peak Flow | Respiratory Rate |
|---|---|---|---|---|
| Mild | Dyspnea with activity; speaks sentences | ≥95% | ≥70% | Normal to mildly elevated |
| Moderate | Dyspnea at rest; speaks phrases | 91-94% | 40-69% | Elevated |
| Severe | Dyspnea at rest; speaks words only | <90% | <40% or unable | Markedly elevated, accessory muscles |
| Life-threatening | Exhausted, confused, silent chest | <90% | Unable | Variable, may be decreasing (fatigue) |
Age-Appropriate Respiratory Rate:
| Age | Normal RR | Elevated RR |
|---|---|---|
| <2 months | <60 | >0 |
| 2-12 months | <50 | >0 |
| 1-5 years | <40 | >0 |
| 6-12 years | <30 | >0 |
| >2 years | <20 | >0 |
Epidemiology
- Prevalence: 8-10% of children in US have asthma
- ED visits: 1.8 million/year (age <18)
- Hospitalizations: 130,000/year
- Deaths: ~170 deaths/year in children
- Risk factors for death: Prior intubation, recent hospitalization, low socioeconomic status, poor adherence
Etiology/Triggers
Common Triggers:
| Category | Triggers |
|---|---|
| Infections | Viral URI (most common—RSV, rhinovirus, influenza) |
| Allergens | Dust mites, pet dander, pollen, mold |
| Irritants | Smoke, pollution, strong odors |
| Exercise | Exercise-induced bronchoconstriction |
| Weather | Cold air, humidity changes |
| Medications | NSAIDs, beta-blockers (rare in children) |
| Emotions | Stress, strong emotions |
Mechanism of Asthma Exacerbation
- Trigger exposure: Viral infection, allergen, irritant
- Airway inflammation: Mast cells, eosinophils, T-lymphocytes
- Bronchial smooth muscle constriction: Bronchoconstriction
- Mucus hypersecretion: Airway plugging
- Airway edema: Mucosal swelling
- Airflow obstruction: Wheeze, air trapping, hyperinflation
- V/Q mismatch: Hypoxemia
- Respiratory muscle fatigue: Hypercapnia (late)
Physiological Changes
| Change | Effect |
|---|---|
| Increased airway resistance | Dyspnea, wheeze |
| Air trapping | Hyperinflation, decreased tidal volume |
| Increased work of breathing | Muscle fatigue, accessory muscle use |
| V/Q mismatch | Hypoxemia |
| Respiratory muscle fatigue | Hypercapnia, respiratory failure |
Why Silent Chest is Dangerous
- Severe obstruction → negligible airflow
- No airflow = no wheeze
- Indicates impending respiratory failure
Symptoms
Typical:
Prodrome (May precede by hours to days):
History
Key Questions:
Physical Examination
Vital Signs:
| Finding | Interpretation |
|---|---|
| Tachypnea | Work of breathing |
| Tachycardia | Hypoxemia, catecholamines, albuterol effect |
| Hypoxia | Severe (SpO2 <92%) |
| Pulsus paradoxus | >0 mmHg = severe obstruction |
Respiratory Examination:
| Finding | Severity |
|---|---|
| Expiratory wheeze | Mild-moderate |
| Inspiratory + expiratory wheeze | Moderate-severe |
| Silent chest (no wheeze) | Life-threatening |
| Prolonged expiratory phase | Obstruction |
| Accessory muscle use | Moderate-severe |
| Intercostal retractions | Severe |
| Subcostal retractions | Severe |
| Nasal flaring | Severe |
| Inability to speak sentences | Severe |
Mental Status:
| Finding | Interpretation |
|---|---|
| Alert, speaks normally | Mild |
| Anxious, speaks phrases | Moderate |
| Agitated, speaks words | Severe |
| Drowsy, confused | Life-threatening |
Signs of Impending Respiratory Failure
| Finding | Concern | Action |
|---|---|---|
| Silent chest | No airflow | Immediate aggressive treatment |
| Drowsiness, confusion | Hypercapnia, hypoxia | Prepare for intubation |
| Cyanosis | Severe hypoxemia | High-flow O2, aggressive treatment |
| SpO2 <90% despite O2 | Severe obstruction | ICU, continuous neb, magnesium |
| Poor response to initial treatment | Refractory | Escalate therapy |
| Unable to speak | Severe obstruction | Aggressive treatment |
| Fatigue, decreased respiratory effort | Impending arrest | Prepare airway |
| Prior ICU admission or intubation | High-risk patient | Low threshold for escalation |
Other Causes of Wheezing in Children
| Diagnosis | Key Features |
|---|---|
| Bronchiolitis | <2 years, viral prodrome, crackles |
| Viral-induced wheeze | <5 years, episodic with viruses, no interval symptoms |
| Foreign body aspiration | Sudden onset, unilateral wheeze, choking history |
| Croup | Barky cough, stridor, hoarse voice |
| Anaphylaxis | Urticaria, angioedema, exposure history |
| Pneumonia | Fever, crackles, focal findings |
| Pertussis | Paroxysmal cough, post-tussive vomiting/whoop |
| Cardiac failure | Murmur, hepatomegaly, cardiomegaly |
| Tracheomalacia | Recurrent wheeze, particularly with exertion |
Clinical Assessment
Primary Assessment:
- Work of breathing
- Mental status
- Ability to speak
- SpO2 on room air
- Response to initial treatment
Peak Expiratory Flow (If child can perform, usually ≥6 years):
- Compare to baseline or predicted
- <50% predicted = severe
- May not be feasible in severe exacerbation
Scoring Systems
Pediatric Asthma Severity Score (PASS) or Pediatric Respiratory Assessment Measure (PRAM):
- Standardized assessment of severity
- Guides therapy escalation
Laboratory Studies
Not routinely required. Consider:
| Test | Indication |
|---|---|
| VBG/ABG | Severe exacerbation, concern for hypercapnia |
| CXR | Suspected pneumonia, pneumothorax, first episode |
| Viral panel | May help with cohorting, prognosis |
VBG/ABG Interpretation in Asthma:
| Finding | Interpretation |
|---|---|
| Low PaCO2 (hyperventilation) | Compensated, mild-moderate |
| Normal PaCO2 | Concerning—may indicate fatigue |
| High PaCO2 (hypercapnia) | Respiratory failure, impending arrest |
When to Image
CXR Indications:
- Fever + localized findings (pneumonia)
- First-ever wheeze (consider foreign body, anatomy)
- Subcutaneous emphysema (pneumothorax/pneumomediastinum)
- Refractory to treatment
- Clinical concern for complication
Principles of Management
- Assess severity: Guide therapy intensity
- Bronchodilation: Albuterol ± ipratropium
- Systemic steroids: Reduce inflammation
- Oxygen: Maintain SpO2 ≥92-94%
- Frequent reassessment: Escalate if not improving
- Avoid intubation if possible: But don't delay if needed
Bronchodilators
Albuterol (Salbutamol) - First-line:
| Severity | Dosing |
|---|---|
| Mild-Moderate | 2.5-5 mg nebulized q20min × 3, then q1-4h |
| Severe | Continuous nebulization 0.5 mg/kg/hr (max 15 mg/hr) |
| MDI option | 4-8 puffs q20min × 3 (with spacer) |
Ipratropium Bromide - Add for moderate-severe:
| Dose | Frequency |
|---|---|
| 250 mcg (<20 kg) / 500 mcg (≥20 kg) | q20min × 3 doses, combined with albuterol |
Epinephrine IM - Impending respiratory failure or severe bronchospasm: | Dose | 0.01 mg/kg of 1:1000 (max 0.3-0.5 mg) |
Systemic Corticosteroids
Give Within First Hour:
| Agent | Dose | Notes |
|---|---|---|
| Prednisolone/Prednisone | 1-2 mg/kg PO (max 60 mg) | 3-5 day course |
| Dexamethasone | 0.6 mg/kg PO/IM (max 16 mg) | Single dose or 2 doses |
| Methylprednisolone | 1-2 mg/kg IV (max 125 mg) | If unable to take PO |
Dexamethasone Advantages: Single dose may be equivalent to 5 days prednisolone; better compliance
Magnesium Sulfate
Indication: Severe exacerbation not responding to initial therapy | Dose | 40-75 mg/kg IV (max 2g) | | Administration | Over 20-30 minutes | | Monitoring | BP, reflexes |
Oxygen Therapy
Goal: SpO2 ≥92-94%
- Nasal cannula for mild hypoxia
- Face mask for moderate
- High-flow nasal cannula for severe
- Non-rebreather if high O2 requirement
High-Flow Nasal Cannula (HFNC):
- May reduce work of breathing
- Consider for severe exacerbation before intubation
- Rates: 2 L/kg/min for infants; 1 L/kg/min for older children (max 50-60 L/min)
Adjunctive Therapies
| Therapy | Indication | Notes |
|---|---|---|
| Heliox | Severe obstruction | 70:30 or 80:20 He:O2; reduces turbulence |
| IV terbutaline | Severe, failed nebulizers | 10 mcg/kg bolus, then 0.4-6 mcg/kg/min |
| IV aminophylline | Rarely used | Narrow therapeutic window, many side effects |
| Ketamine | Sedation for intubation | Bronchodilating properties |
| Non-invasive ventilation | Selected patients | BiPAP for severe work of breathing |
Intubation (Last Resort)
Indications:
- Respiratory arrest
- Severe hypoxemia despite aggressive therapy
- Altered mental status / exhaustion
- Rising PaCO2 with acidosis
Considerations:
- Difficult airway (bronchospasm, dynamic hyperinflation)
- Ketamine is preferred induction agent (bronchodilator)
- High airway pressures expected
- Risk of barotrauma
- Low respiratory rate to allow expiration (permissive hypercapnia)
Treatment Algorithm by Severity
| Severity | Initial Treatment |
|---|---|
| Mild | Albuterol q20min × 3, steroids, reassess |
| Moderate | Albuterol + ipratropium q20min × 3, steroids, O2, reassess |
| Severe | Continuous albuterol, ipratropium, steroids, magnesium, O2, ICU |
| Life-threatening | All above + prepare for intubation, epinephrine |
Discharge Criteria
- Good response to treatment (sustained ≥1 hour after last treatment)
- SpO2 ≥94% on room air
- Minimal to no wheeze
- No retractions
- Tolerating oral steroids
- Able to use inhaler properly
- Family education completed
- Follow-up arranged (24-72 hours)
Admission Criteria
- Persistent hypoxia (SpO2 <92% on room air)
- Persistent respiratory distress after initial treatment
- Inadequate response to ED treatment
- Prior ICU admission or intubation (high-risk)
- Unable to tolerate oral steroids
- Social concerns, unable to follow up
- Need for q1-2h bronchodilators
ICU Admission Criteria
- Severe exacerbation not responding to treatment
- Need for continuous albuterol
- Hypercapnia or rising PaCO2
- Altered mental status
- Impending respiratory failure
- Need for intubation
Follow-Up
| Situation | Follow-Up |
|---|---|
| Discharged from ED | PCP in 24-72 hours |
| Hospitalized | PCP within 1 week; pulm/allergy if recurrent |
| Multiple ED visits | Asthma specialist referral |
Condition Explanation (For Parents)
- "Your child is having an asthma attack, which means their airways are narrowed and inflamed."
- "We are giving medicine to open up the airways and reduce the swelling."
- "It's important to complete the steroid course to prevent the attack from coming back."
Discharge Instructions
- Complete steroid course (prednisolone for 3-5 days or dexamethasone as prescribed)
- Continue rescue inhaler as needed (with spacer)
- Resume controller medications
- Avoid known triggers
- Follow up as scheduled
Warning Signs (Return immediately)
- Worsening breathing difficulty
- Rescue inhaler not helping
- Unable to speak or drink
- Lips or nails turning blue
- Child becoming very sleepy or confused
Prevent Future Attacks
- Controller medication adherence (ICS)
- Avoid triggers
- Written asthma action plan
- Influenza vaccination yearly
- Follow up with primary care/specialist
Infants (<12 months)
- Diagnosis of asthma uncertain (may be bronchiolitis, viral wheeze)
- Response to bronchodilators may be less predictable
- Higher risk for complications
- Low threshold for admission
Adolescents
- Adherence issues common
- Assess for tobacco/vaping/marijuana use
- Mental health comorbidities
- Transition planning to adult care
Known High-Risk Patients
- Prior ICU admission or intubation
- ≥3 ED visits or ≥2 hospitalizations in past year
- Recent oral steroid use
- Poor adherence to controller therapy
- Significant allergies
- Low threshold for escalation and admission
Performance Indicators
| Metric | Target | Rationale |
|---|---|---|
| Time to first bronchodilator | <30 minutes | Rapid treatment |
| Steroids given within 1 hour | >0% | Reduce inflammation early |
| SpO2 documented | 100% | Severity assessment |
| Discharge with asthma action plan | >0% | Prevent recurrence |
| Follow-up within 72h arranged | >0% | Continuity of care |
Documentation Requirements
- Baseline asthma severity and control
- Current medications
- Trigger for exacerbation
- Physical exam including severity assessment
- Response to treatment
- Discharge medications and instructions
- Follow-up plan
Diagnostic Pearls
- Silent chest = severe obstruction: Not improving, just worse
- Normal or rising PaCO2 is a red flag: Patient tiring
- Paradoxical breathing in infants: Sign of fatigue
- Not all wheeze is asthma: Consider foreign body, cardiac, etc.
- First wheeze in <12 months: May not be asthma
- Pulsus paradoxus >20 mmHg: Severe obstruction
Treatment Pearls
- Steroids within 1 hour: Reduces admissions
- Continuous nebs for severe: Not PRN
- Ipratropium only in first hour: No benefit later
- Dexamethasone 1-2 doses: May equal 5-day prednisolone
- Magnesium for severe: Give before intubation
- Ketamine for intubation: Bronchodilator properties
Disposition Pearls
- Discharge only if sustained improvement: 1+ hour after last treatment
- Low threshold to admit high-risk patients: Prior intubation, frequent visits
- Written asthma action plan: Prevents future attacks
- Follow-up is critical: 24-72 hours
- Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention (2023 Update).
- National Asthma Education and Prevention Program Expert Panel Report 3 (EPR-3). Guidelines for the Diagnosis and Management of Asthma. NIH Publication No. 08-4051. 2007.
- Keeney GE, et al. Dexamethasone for acute asthma exacerbations in children: a meta-analysis. Pediatrics. 2014;133(3):493-499.
- Rowe BH, et al. Corticosteroid therapy for acute asthma. Respir Med. 2004;98(4):275-284.
- Cheuk DK, et al. A meta-analysis on intravenous magnesium sulphate for treating acute asthma. Arch Dis Child. 2005;90(1):74-77.
- British Thoracic Society/Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma. 2019.
- Camargo CA Jr, et al. Emergency Medicine Network Investigators. Management of acute asthma in US emergency departments. Acad Emerg Med. 2003;10(4):364-372.
- UpToDate. Acute asthma exacerbations in children younger than 12 years: Emergency department management. 2024.